Results of the NLG2105 Phase I Trial Using the IDO Pathway Inhibitor Indoximod, in Combination with Radiation and Chemotherapy, for Children with Newly Diagnosed DIPG

This article has no abstract
Epistemonikos ID: c702d2cd83a3b503fbbbfbfc59d58a55a57d6c62
First added on: Feb 11, 2025